Nkarta, Inc. Files Q1 2025 10-Q
Ticker: NKTX · Form: 10-Q · Filed: May 14, 2025 · CIK: 1787400
| Field | Detail |
|---|---|
| Company | Nkarta, INC. (NKTX) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: NKTX
TL;DR
Nkarta's Q1 2025 10-Q is in: cash looks okay, equity changes noted. #biotech
AI Summary
Nkarta, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial items include cash and cash equivalents, and additional paid-in capital. The filing also details equity incentive plan activity and restricted stock units.
Why It Matters
This filing provides investors with the latest financial snapshot of Nkarta, Inc., including their cash position and equity changes, crucial for understanding their operational runway and financial health.
Risk Assessment
Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (The end date for the financial information presented in the 10-Q.)
- 2025-05-14 — Filing Date (The date Nkarta, Inc. submitted this 10-Q to the SEC.)
- 2024-12-31 — Prior Year End Date (Reference point for comparative financial data from the previous fiscal year.)
Key Players & Entities
- Nkarta, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Date the filing was made
- 0000950170-25-071455 (accession_number) — Unique identifier for the filing
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Standard Industrial Classification code for Nkarta, Inc.
- 1150 VETERANS BOULEVARD (address) — Business and mailing address of Nkarta, Inc.
- SOUTH SAN FRANCISCO, CA 94080 (address) — Business and mailing address of Nkarta, Inc.
- us-gaap:RestrictedStockUnitsRSUMember (financial_metric) — Reporting of Restricted Stock Units
- us-gaap:CashEquivalentsMember (financial_metric) — Reporting of cash and cash equivalents
- us-gaap:AdditionalPaidInCapitalMember (financial_metric) — Reporting of additional paid-in capital
FAQ
What was Nkarta, Inc.'s cash and cash equivalents balance as of March 31, 2025?
The filing indicates reporting for 'us-gaap:CashEquivalentsMember' for the period ending March 31, 2025, but the specific dollar amount is not provided in this excerpt.
What is the company's Standard Industrial Classification (SIC) code?
Nkarta, Inc.'s SIC code is 'PHARMACEUTICAL PREPARATIONS [2834]'.
When did the reporting period for this 10-Q filing conclude?
The Conformed Period of Report is 20250331, meaning the reporting period concluded on March 31, 2025.
What is the business address of Nkarta, Inc.?
The business address is 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA 94080.
What type of equity awards are mentioned in the filing?
The filing mentions 'us-gaap:RestrictedStockUnitsRSUMember' and details related to the 'nktx:EquityIncentivePlanMember'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Nkarta, Inc. (NKTX).